Biogen Inc. ((BIIB)), Denali Therapeutics ((DNLI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biogen Inc. and Denali Therapeutics have launched a Phase 2a study titled ‘A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD).’ The study aims to assess the safety, tolerability, and pharmacodynamic effects of BIIB122 in individuals with LRRK2-PD, a form of Parkinson’s Disease linked to a genetic variant that increases LRRK2 kinase activity.
The intervention being tested is BIIB122, an oral drug administered at a 225 mg dose once daily. The study also includes a placebo group receiving a matching placebo. The primary goal is to evaluate the treatment’s safety and pharmacodynamic effects.
This interventional study is randomized with a parallel assignment. It employs a double-blind masking approach, ensuring that both participants and investigators are unaware of the group assignments. The primary purpose of the study is treatment-focused.
The study began on September 16, 2024, with a primary completion date yet to be announced. The last update was submitted on July 28, 2025. These dates are crucial as they mark the progress and updates in the study timeline.
The update on this study could influence Biogen and Denali Therapeutics’ stock performance, as positive results may boost investor confidence and interest. This study is significant in the competitive landscape of Parkinson’s Disease treatments, where advancements can lead to substantial market shifts.
The study is ongoing, with further details available on the ClinicalTrials portal.